Biotech News

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia (NTLA)Intellia2026-05-11 11:30 ESTEarnings

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including

Open original release

Related news

NTLAIntellia2026-04-27 11:00 EST

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

SRPTSarepta Therapeutics2026-04-22 12:30 EST

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

ABEOAbeona Therapeutics2026-03-17 11:30 EST

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

CRSPCRISPR Therapeutics2026-02-12 21:30 EST

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

SANASana Biotechnology2026-03-03 21:05 EST

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

View all latest news

Intellia

Intellia Therapeutics is a gene-editing company building in vivo and ex vivo CRISPR programs across serious genetic diseases.

Recent company news

NTLAIntellia2026-07-06 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLAIntellia2026-06-05 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-01 11:30 EST

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

NTLAIntellia2026-05-11 11:30 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Stock data

Close: 10.67 USD
Market cap: 1.83B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States